Vor Biopharma, Inc. (VOR)
22.71
-0.65
(-2.78%)
USD |
NASDAQ |
Aug 24, 16:00
22.71
0.00 (0.00%)
After-Hours: 20:00
Vor Biopharma Shareholders Equity (Quarterly) : -200.20M for June 30, 2026
Shareholders Equity (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Shareholders Equity (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -200.20M |
| March 31, 2026 | -150.42M |
| December 31, 2025 | -164.31M |
| September 30, 2025 | -2.225B |
| June 30, 2025 | -1.506B |
| March 31, 2025 | 66.07M |
| December 31, 2024 | 96.66M |
| September 30, 2024 | 72.96M |
| June 30, 2024 | 98.08M |
| March 31, 2024 | 123.04M |
| December 31, 2023 | 150.72M |
| September 30, 2023 | 174.78M |
| June 30, 2023 | 204.45M |
| March 31, 2023 | 230.22M |
| Date | Value |
|---|---|
| December 31, 2022 | 250.61M |
| September 30, 2022 | 158.73M |
| June 30, 2022 | 174.97M |
| March 31, 2022 | 194.45M |
| December 31, 2021 | 216.26M |
| September 30, 2021 | 232.96M |
| June 30, 2021 | 250.11M |
| March 31, 2021 | 267.19M |
| December 31, 2020 | 48.27M |
| September 30, 2020 | 63.19M |
| June 30, 2020 | |
| March 31, 2020 | |
| December 31, 2019 | 7.64M |
Shareholders' Equity Definition
Represents the value of Shareholders' Equity as of the close of the report date, belonging to both Preferred and Common Equity Shareholders.
Shareholders Equity (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Shareholders Equity (Quarterly) Benchmarks
| Dyne Therapeutics, Inc. | 702.15M |
| Agenus, Inc. | -199.08M |
| Amgen, Inc. | 11.69B |
| Anika Therapeutics, Inc. | 137.28M |
| BioCryst Pharmaceuticals, Inc. | -454.29M |
Shareholders Equity (Quarterly) Related Metrics
| Total Assets (Quarterly) | 481.05M |
| Total Liabilities (Quarterly) | 681.25M |
| Debt to Equity Ratio | -0.0144 |
| Current Ratio | 19.15 |
| Net Debt Paydown Yield | 0.56% |